Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: An update and review of the literature

Oncologist

Volumn 14, Issue 8, 2009, Pages 816-827

  Armstrong, Andrew J ^a   Febbo, Phillip G ^a  

^a DUKE CANCER INSTITUTE   (United States)

Author keywords

Prostate cancer; Prostate specific antigen; src family kinases; Surrogate markers

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; DASATINIB; ENZYME INHIBITOR; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; NMS 354825; PROSTATE SPECIFIC ANTIGEN; PROTEIN TYROSINE KINASE; SRC KINASE INHIBITOR; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; BONE METABOLISM; BONE PAIN; BONE SCINTISCANNING; BONE TURNOVER; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CASTRATION; CHRONIC MYELOID LEUKEMIA; CLINICAL RESEARCH; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE MARKER; DRUG INHIBITION; ENZYME INHIBITION; HUMAN; MEDICAL LITERATURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW;

DISEASE-FREE SURVIVAL; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 70249141721     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0043     Document Type: Review

References (78)

1. Scher HI, Heller G. Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology 2000;55:323-327. (Pubitemid 30110575)
2. Mendiratta P, Febbo PG. Genomic signatures associated with the development, progression, and outcome of prostate cancer. Mol Diagn Ther 2007;11:345-354. (Pubitemid 350274403)
3. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23:8253-8261.
4. Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008;8:440-448.
5. Carducci MA, Padley RJ, Breul J et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003;21:679-689. (Pubitemid 46621903)
6. Carducci MA, Saad F, Abrahamsson PA et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007;110:1959-1966. (Pubitemid 350036854)
7. Higano C, Saad F, Somer B et al. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC). J Clin Oncol (ASCO Genitourinary Cancers Symposium Abstracts) 2009;(abstract LBA150).
8. Schwartz GG. Vitamin D and intervention trials in prostate cancer: from theory to therapy. Ann Epidemiol 2009;19:96-102.
9. Small E, Demkow T, Gerritsen WR et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). J Clin Oncol (ASCO Genitourinary Cancers Symposium Abstracts) 2009;(abstract 7).
10. Sartor AO, Petrylak DP, Witjes JA et al. Satraplatin in patients with advanced hormone-refractory prostate cancer (HRPC): overall survival (OS) results from the phase III satraplatin and prednisone against refractory cancer (SPARC) trial. J Clin Oncol 2008;26(May 20 suppl):250s (abstract 5003).
11. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer 2004;4:470-480.
12. Fizazi K. The role of Src in prostate cancer. Ann Oncol 2007;18:1765-1773.
13. Yu EY, Wilding G, Posadas E et al. Dasatinib in patients with hormone-refractory progressive prostate cancer: a phase II study. J Clin Oncol 2008;26(May 20 suppl):288s (abstract 5156).
14. Bubley GJ, Carducci M, Dahut W et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461-3467. (Pubitemid 29517916)
15. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
16. Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148-1159.
17. Chen CD, Welsbie DS, Tran C et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-39. (Pubitemid 38524696)
18. Stanbrough M, Bubley GJ, Ross K et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66:2815-2825.
19. Armstrong AJ, Garrett-Mayer E, Ou Yang YC et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 2007;25:3965-3970. (Pubitemid 47477275)
20. Miles AK, Rogers A, Parkinson R et al. Overview of prostate biomarkers as potential targets for immunotherapy. Curr Cancer Ther Rev 2008;4:86-95.
21. Petrylak DP, Ankerst DP, Jiang CS et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006;98:516-521.
22. Armstrong AJ, Garrett-Mayer ES, Yang YC et al. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 2007;13:6396-6403.
23. Febbo PG. Epigenetic events highlight the challenge of validating prognostic biomarkers during the clinical and biologic evolution of prostate cancer. J Clin Oncol 2009;27:3088-3090.
24. Berthold DR, Pond GR, Roessner M et al. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 2008;14:2763-2767.
25. Halabi S, Vogelzang NJ, Ou SS et al. Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J Clin Oncol 2009;27:2766-2771.
26. Hussain M, Goldman B, Tangen C et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol 2009;27:2450-2456.
27. Scher HI, Warren M, Heller G. The association between measures of progression and survival in castrate-metastatic prostate cancer. Clin Cancer Res 2007;13:1488-1492. (Pubitemid 46450439)
28. Fleming TR, Rothmann MD, Lu HL. Issues in using progression-free survival when evaluating oncology products. J Clin Oncol 2009;27:2874-2880.
29. Petrylak D, Sartor AO, Witjes JA et al. A phase III, randomized, double-blind trial of satraplatin and prednisone vs placebo and prednisone for patients with hormone refractory prostate cancer (HRPC). J Clin Oncol (2007 Prostate Cancer Symposium) 2007;(abstract 145).
30. Schellhammer PF, Higano C, Berger ER et al. A randomized, double-blind, placebo-controlled, multi-center, phase III trial of sipuleucel-T in men with metastatic, androgen independent prostatic adenocarcinoma (AIPC). Abstract presented at: American Urological Association Annual Meeting; April 25-30, 2009; Chicago. Abstract LBA9.
31. Scher HI, Morris MJ, Kelly WK et al. Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin Cancer Res 2005;11:5223-5232.
32. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
33. Hricak H, Choyke PL, Eberhardt SC et al. Imaging prostate cancer: a multidisciplinary perspective. Radiology 2007;243:28-53. (Pubitemid 46579693)
34. Sella A, Konichezky M, Flex D et al. Low PSA metastatic androgen-independent prostate cancer. Eur Urol 2000;38:250-254. (Pubitemid 30665949)
35. Slovin SF. Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior. Nat Clin Pract Oncol 2007;4:551-554.
36. Soerdjbalie-Maikoe V, Pelger RC, Nijeholt GA et al. Bone scintigraphy predicts the risk of spinal cord compression in hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging 2004;31:958-963. (Pubitemid 38915650)
37. Lecouvet FE, Geukens D, Stainier A et al. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol 2007;25:3281-3287. (Pubitemid 47325613)
38. Vessella RL, Corey E. Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis. Clin Cancer Res 2006;12:6285s-6290s. (Pubitemid 44703804)
39. Msaouel P, Pissimissis N, Halapas A et al. Mechanisms of bone metastasis in prostate cancer: clinical implications. Best Pract Res Clin Endocrinol Metab 2008;22:341-355. (Pubitemid 351611957)
40. Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Cancer 2000;88:2919-2926.
41. Coleman RE, Major P, Lipton A et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005;23:4925-4935. (Pubitemid 46223998)
42. Halabi S, Small EJ, Kantoff PW et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003;21:1232-1237. (Pubitemid 46606398)
43. Smaletz O, Scher HI, Small EJ et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002;20:3972-3982.
44. Rajpar S, Laplanche A, Tournay E et al. Prognostic value of urinary N-telopeptide (uNTx) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases. J Clin Oncol 2008;26(May 20 suppl):283s (abstract 5138).
45. Smith MR, Cook RJ, Coleman R et al. Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Urology 2007;70:315-319. (Pubitemid 47362256)
46. Brown MW, Singh AK. Alkaline phosphatase level increase with initiation of hormone therapy for prostate cancer portends poor prognosis with rapid progression to bone metastases: a case report and review of the literature. Clin Genitourin Cancer 2006;4:293-295.
47. Cook RJ, Coleman R, Brown J et al. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res 2006;12:3361-3367. (Pubitemid 43910880)
48. Armstrong AJ, Febbo PG, George DJ et al. Systemic strategies for prostate cancer. Minerva Urol Nefrol 2007;59:11-25.
49. Berthold DR, Pond GR, Soban F et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26:242-245.
50. Halabi S, Vogelzang NJ, Kornblith AB et al. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol 2008;26:2544-2549.
51. Ramiah V, George DJ, Armstrong AJ. Clinical endpoints for drug development in prostate cancer. Curr Opin Urol 2008;18:303-308.
52. Danila DC, Heller G, Gignac GA et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007;13:7053-7058. (Pubitemid 350276887)
53. Moreno J, de Bono JS, Shaffer D et al. Multi-center study evaluating circulating tumor cells (CTCs) as a surrogate for survival in men treated for castration refractory prostate cancer (CRPC). J Clin Oncol 2007;25(June 20 suppl):239s (abstract 5016).
54. de Bono JS, Scher HI, Montgomery RB et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14:6302-6309.
55. Scher HI, Jia X, de Bono JS et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 2009;10:233-239.
56. Goodman OB Jr, Fink LM, Symanowski JT et al. Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors. Cancer Epidemiol Biomarkers Prev 2009;18:1904-1913.
57. Shaffer DR, Leversha MA, Danila DC et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 2007;13:2023-2029. (Pubitemid 46649868)
58. Attard G, Reid AH, Olmos D et al. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res 2009;69:4937-4940.
59. Smirnov DA, Zweitzig DR, Foulk BW et al. Global gene expression profiling of circulating tumor cells. Cancer Res 2005;65:4993-4997. (Pubitemid 40827303)
60. Weckermann D, Polzer B, Ragg T et al. Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol 2009;27:1549-1556.
61. Maheswaran S, Sequist LV, Nagrath S et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359:366-377.
62. Nagrath S, Sequist LV, Maheswaran S et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007;450:1235-1239.
63. Nam S, Kim D, Cheng JQ et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005;65:9185-9189. (Pubitemid 41507982)
64. Recchia I, Rucci N, Festuccia C et al. Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro. Eur J Cancer 2003;39:1927-1935. (Pubitemid 37311191)
65. Slack JK, Adams RB, Rovin JD et al. Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells. Oncogene 2001;20:1152-1163.
66. Goldenberg-Furmanov M, Stein I, Pikarsky E et al. Lyn is a target gene for prostate cancer: sequence-based inhibition induces regression of human tumor xenografts. Cancer Res 2004;64:1058-1066. (Pubitemid 38176910)
67. Summy JM, Gallick GE. Treatment for advanced tumors: SRC reclaims center stage. Clin Cancer Res 2006;12:1398-1401.
68. Kopetz S, Shah AN, Gallick GE. Src continues aging: current and future clinical directions. Clin Cancer Res 2007;13:7232-7236.
69. Lombardo LJ, Lee FY, Chen P et al. Discovery of N-(2-chloro-6- methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658-6661. (Pubitemid 40053752)
70. Park SI, Zhang J, Phillips KA et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008;68:3323-3333.
71. Zeng G, Hu Z, Kinch MS et al. High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol 2003;163:2271-2276. (Pubitemid 37466471)
72. Walker-Daniels J, Coffman K, Azimi M et al. Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate 1999;41:275-280.
73. Smith MR, Manola J, Kaufman DS et al. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer 2004;101:1569-1574. (Pubitemid 39318903)
74. Araujo J, Armstrong AJ, Braud EL et al. Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: a phase I/II study (CA180086). J Clin Oncol 2009;27(suppl) (abstract 5061).
75. Wang XD, Reeves K, Luo FR et al. Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring. Genome Biol 2007;8:R255. (Pubitemid 351917494)
76. Luo FR, Barrett YC, Yang Z et al. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor. Cancer Chemother Pharmacol 2008;62:1065-1074.
77. Bild AH, Yao G, Chang JT et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-357. (Pubitemid 43128862)
78. Mendiratta P, Mostaghel E, Guinney J et al. Genomic strategy for targeting therapy in castration-resistant prostate cancer. J Clin Oncol 2009;27:2022-2029.